...
首页> 外文期刊>Advanced drug delivery reviews >Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems
【24h】

Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems

机译:脂质纳米粒子和细胞外囊泡的微流体和药物递送系统中的应用进展

获取原文
获取原文并翻译 | 示例
           

摘要

Lipid-based nanobiomaterials as liposomes and lipid nanoparticles (LNPs) are the most widely used nanocarriers for drug delivery systems (DDSs). Extracellular vesicles (EVs) and exosomes are also expected to be applied as DDS nanocarriers. The performance of nanomedicines relies on their components such as lipids, targeting ligands, encapsulated DNA, encapsulated RNA, and drugs. Recently, the importance of the nanocarrier sizes smaller than 100 nm is attracting attention as a means to improve nanomedicine performance. Microfluidics and lab-on-a chip technologies make it possible to produce size-controlled LNPs by a simple continuous flow process and to separate EVs from blood samples by using a surface marker, ligand, or electric charge or by making a mass or particle size discrimination. Here, we overview recent advances in microfluidic devices and techniques for liposomes, LNPs, and EVs and their applications for DDSs. (C) 2018 Elsevier B.V. All rights reserved.
机译:基于脂质的纳米双层材料作为脂质体和脂质纳米颗粒(LNP)是用于药物递送系统(DDSS)的最广泛使用的纳米骨载体。 预期外细胞外囊泡(EVS)和外泌体也适用于DDS纳米载体。 纳米胺的性能依赖于它们的组分,例如脂质,靶向配体,包封的DNA,包封的RNA和药物。 最近,纳米载波尺寸小于100nm的重要性是吸引注意力,以提高纳米医疗性能的手段。 微流体和实验室芯片技术可以通过简单的连续流程工艺产生大小控制的LNP,并通过使用表面标记,配体或电荷或通过制造质量或粒度来分离来自血液样本的EV。 歧视。 在这里,我们概述了微流体装置和脂质体,LNP和EVS技术的最新进展及其DDS的应用。 (c)2018 Elsevier B.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号